CoChat
Sign Up
Cited by 269Hormonal and reproductive studiesNutrition and Health in AgingLiver Disease and Transplantation

The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.

Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: A randomised controlled trial

Sinclair, Marie, Grossmann, Mathis, Hoermann, Rudolf, Angus, Peter W., Gow, Paul J.·2016·Journal of Hepatology
DOI 10.1016/j.jhep.2016.06.007
Open this paper in CoChat — free account

Abstract

Background & aims Low testosterone and sarcopenia are common in men with cirrhosis and both are associated with increased mortality. Whether testosterone therapy in cirrhosis improves muscle mass and other outcomes is unknown.Methods We conducted a 12-month, double-blinded, placebo-controlled trial of intramuscular testosterone undecanoate in 101 men with established cirrhosis and low serum testosterone (total testosterone <12nmol/L or free testosterone <230pmol/L) in a single tertiary centre. Body composition was assessed using dual-energy X-ray absorptiometry at baseline, 6 and 12months.Results At study completion, appendicular lean mass was significant higher in testosterone-treated subjects, with a mean adjusted difference (MAD) of +1.69kg, (CI +0.40; +2.97kg, p=0.021). Secondary outcomes included a substantially higher total lean mass in the active group (MAD +4.74kg, CI +1.75; +7.74kg, p=0.008), matched by reduced fat mass (MAD -4.34kg, CI -6.65; -2.04, p<0.001). Total bone mass increased (MAD +0.08kg, CI +0.01; +0.15kg, p=0.009) as did bone mineral density at the femoral neck (MAD +0.287points, CI +0.140; +0.434, p<0.001). Haemoglobin was higher with testosterone therapy (MAD +10.2g/L, CI +1.50; +18.9g/L, p=0.041) and percentage glycosylated haemoglobin (HbA1c) lower (MAD -0.35%, CI -0.05; -0.54, p=0.028). Mortality was non-significantly lower in testosterone-treated patients (16% vs. 25.5%, p=0.352). There was no increase in adverse events in testosterone-treated subjects.Conclusion Testosterone therapy in men with cirrhosis and low serum testosterone safely increases muscle mass, bone mass and haemoglobin, and reduces fat mass and HbA1c. This is the first evidence-based therapy for sarcopenia in cirrhosis and thus requires larger-scale investigation into its potential impact on mortality.Lay summary Both low testosterone and muscle wasting are associated with increased risk of death in men with severe liver disease. Administering testosterone to men with liver disease who have low testosterone levels significantly increases their muscle mass. In addition, testosterone has non-muscle beneficial effects which may be able to increase survival in this population.Clinical trial number Australian New Zealand Clinical Trials Registry trial number ACTRN 12614000526673.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2016.06.007

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 56 references

Research works printed but not linked: 1

  1. Soriano, 2013, Reply: To PMID 22213000, Hepatology, 57, 1284

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Sinclair, M., Grossmann, M., Hoermann, R., Angus, P. W., & Gow, P. J.
Affiliations
The University of Melbourne (AU)
Corresponding author
Sinclair, Marie
ORCID
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2016-11
Volume
65
Issue
5
Pages
906-913
ISSN
0168-8278 (ISSN-L)
DOI
10.1016/j.jhep.2016.06.007
OpenAlex
W2423926234
Cited by
269
References
56
Citations by year
2026: 21 · 2025: 24 · 2024: 30 · 2023: 32 · 2022: 28 · 2021: 27 · 2020: 25 · 2019: 30 · 2018: 28 · 2017: 18 · 2016: 4
FWCI
26.78
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Journal of Hepatology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Novartis
  • Bayer Schering
  • University of Melbourne
  • National Health and Medical Research Council (1024139)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
Keywords
testosterone replacement therapy, testosterone undecanoate, liver cirrhosis, androgen deficiency, sarcopenia, muscle mass, lean body mass, fat mass, bone mineral density, hemoglobin, HbA1c, mortality, men, body composition, sex hormones, adverse events, safety and tolerability, quality of life, quality-adjusted life years
MeSH terms
Australia, Body Composition, Humans, Liver Cirrhosis, Male, Testosterone, Absorptiometry, Photon, Muscle, Skeletal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review